Kromek Group Plc

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00BD7V5D43
GBP
0.07
0 (0.78%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a growth in Net Profit of 197.77%, the company declared Very Positive results in Oct 24

  • OPERATING CASH FLOW(Y) Highest at GBP 0.15 MM
2

With ROE of 7.19%, it has a very attractive valuation with a 0.77 Price to Book Value

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 43 Million (Micro Cap)

stock-summary
P/E

11.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.02

stock-summary
Return on Equity

7.19%

stock-summary
Price to Book

0.82

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
35.42%
0%
35.42%
6 Months
7.44%
0%
7.44%
1 Year
20.37%
0%
20.37%
2 Years
35.42%
0%
35.42%
3 Years
-33.33%
0%
-33.33%
4 Years
-49.96%
0%
-49.96%
5 Years
-46.37%
0%
-46.37%

Kromek Group Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
15.11%
EBIT Growth (5y)
24.57%
EBIT to Interest (avg)
-5.04
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.28
Sales to Capital Employed (avg)
0.29
Tax Ratio
3.73%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
0.77
EV to EBIT
8.29
EV to EBITDA
4.31
EV to Capital Employed
0.76
EV to Sales
1.48
PEG Ratio
0.05
Dividend Yield
NA
ROCE (Latest)
9.22%
ROE (Latest)
7.19%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bullish
Bullish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Kromek Group Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Apr'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Apr 2023 is 42.98% vs 16.35% in Apr 2022",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Apr 2023 is -24.49% vs 9.26% in Apr 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Apr'23",
        "Apr'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "17.30",
          "val2": "12.10",
          "chgp": "42.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.60",
          "val2": "-2.60",
          "chgp": "38.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.20",
          "val2": "0.60",
          "chgp": "100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.10",
          "val2": "1.50",
          "chgp": "-93.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.10",
          "val2": "-4.90",
          "chgp": "-24.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-366.60%",
          "val2": "-578.00%",
          "chgp": "21.14%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Apr'23stock-summary
Apr'23
Apr'22
Change(%)
Net Sales
17.30
12.10
42.98%
Operating Profit (PBDIT) excl Other Income
-1.60
-2.60
38.46%
Interest
1.20
0.60
100.00%
Exceptional Items
0.10
1.50
-93.33%
Consolidate Net Profit
-6.10
-4.90
-24.49%
Operating Profit Margin (Excl OI)
-366.60%
-578.00%
21.14%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Apr 2023 is 42.98% vs 16.35% in Apr 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Apr 2023 is -24.49% vs 9.26% in Apr 2022

stock-summaryCompany CV
About Kromek Group Plc stock-summary
stock-summary
Kromek Group Plc
Pharmaceuticals & Biotechnology
Kromek Group plc is a radiation detection technology company. The Company develops radiation detectors based on cadmium zinc telluride. The Company's segments are UK Operations and US Operations. The Company designs, develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets. The Company's solutions provide information on material composition and structure to enable the identification of cancerous tissues and hazardous materials (including explosives), and the analysis of radioactive materials. Its nuclear products include CPG, GR1-Gamma Ray Spectrometer, GR1A, SIGMA, TN15, RayMon10, Quant Air and RENA-Mini Development Platform. It offers detectors and subcomponents for original equipment manufacturer (OEM) customers in the medical imaging market, including computed tomography (CT), single photon emission computed tomography (SPECT), positron emission tomography (PET) and bone mineral densitometry.
Company Coordinates stock-summary
Company Details
Netpark Incubator, Thomas Wright Way , STOCKTON-ON-TEES None : TS21 3FD
stock-summary
Tel: 44 1740 626060
stock-summary
Registrar Details